Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial
Principal Investigator
Mark Hurwitz, MD
Status
Terminated
Date Closed to Accrual
September 09 2010
Date of Study Termination
May 14 2018
Disease Site
Genitourinary [GU]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess whether the addition of androgen suppression therapy (AST) and docetaxel to adjuvant radiation therapy (ART) improves freedom from progression (FFP) as defined as PSA < 0.4 ng/ml, and no clinical failure (local-regional, or distant failure) at 3 years.
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Pathologically proven diagnosis of adenocarcinoma of the prostate meeting one of the following combinations:
Gleason score > = 7 at the time of prostatectomy and PSA nadir > 0.2ng/ml;
Gleason score > = 8 at the time of prostatectomy and T classification > = T3a.
Target Accrual
76
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.